Homoarginine Supplementation in Patients After Stroke

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This study represents a follow-up of the previous study "Single and Multiple Doses of an Oral Formulation of L-Homoarginine in Healthy Human Subjects" (NCT02675660). This study will evaluate the applicability of an oral formulation of L-homoarginine to normalize homoarginine blood levels in patients with acute ischemic stroke.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT05022979` - Prevalence and Risk Factors for Micronutrient Deficiencies During Pregnancy in Cayenne, French Guiana

NCT number	NCT03692234
Study type	Interventional
Source	Universitätsklinikum Hamburg-Eppendorf
Contact	Chi-un Choe, MD
Phone	+49407410
Email	cchoe@uke.de
Status	Recruiting
Phase	N/A
Start date	August 22, 2018
Completion date	August 2023

Homoarginine Supplementation in Patients After Stroke — HiS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms